00348.HK
China Healthwise Holdings Limited
HKSE · Healthcare · Medical - Pharmaceuticals · HK
HKD 0.07
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 103.2M | 99.6M | 113.6M | 146.3M | 142.1M |
| Cost of Revenue | 78.4M | 62.4M | 78.6M | 86.0M | 88.8M |
| Gross Profit | 24.8M | 37.2M | 35.0M | 60.3M | 53.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 49.7M | 49.9M | 55.5M | 65.4M | 66.9M |
| General & Admin Expense | 13.8M | 21.6M | 26.4M | 37.5M | 38.3M |
| Selling & Marketing Expense | 35.9M | 28.2M | 29.0M | 27.9M | 28.5M |
| Other Expenses | 11.0M | — | — | — | (2.6M) |
| Total Operating Expenses | 60.7M | 49.9M | 55.5M | 65.4M | 64.3M |
| Cost and Expenses | 139.1M | 112.2M | 134.0M | 258.9M | 180.4M |
| Operating Income (EBIT) | (35.9M) | (12.7M) | (20.5M) | (112.6M) | (38.4M) |
| Non-Operating | |||||
| Interest Income | 3.0K | — | — | — | — |
| Interest Expense | 10.3M | 13.8M | 8.3M | 9.0M | 7.3M |
| Net Interest Income | (20.5M) | (13.8M) | (8.3M) | (9.0M) | (7.3M) |
| Other Non-Op Income/Expense | (14.4M) | 9.4M | (19.6M) | (19.5M) | (18.0M) |
| Non-Operating Income (excl Interest) | — | — | 11.3M | 10.5M | 10.7M |
| EBT (Pre-Tax Income) | (50.3M) | (3.3M) | (40.0M) | (132.1M) | (56.4M) |
| Income Tax Expense | (1.2M) | 686.0K | 253.0K | 2.5M | (2.1M) |
| Bottom Line | |||||
| Net Income | (33.1M) | (2.6M) | (40.3M) | (134.6M) | (54.3M) |
| Earnings from Cont. Ops | (49.7M) | (2.6M) | (40.3M) | (134.6M) | (54.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (33.1M) | (2.6M) | (40.3M) | (134.6M) | (54.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.04) | (HK$0.00) | (HK$0.05) | (HK$0.17) | (HK$0.07) |
| Diluted EPS | (HK$0.04) | (HK$0.00) | (HK$0.05) | (HK$0.17) | (HK$0.07) |
| Revenue Per Share | HK$0.13 | HK$0.13 | HK$0.15 | HK$0.19 | HK$0.18 |
| Shares | |||||
| Basic Shares Outstanding | 770.5M | 770.5M | 770.5M | 770.5M | 770.5M |
| Diluted Shares Outstanding | 770.5M | 770.5M | 770.5M | 770.5M | 770.5M |
| Profitability Metrics | |||||
| EBITDA | (27.0M) | (12.3M) | (20.1M) | (117.5M) | (45.8M) |
| D&A | 287.0K | 329.0K | 383.0K | 5.6M | 3.3M |
| EBIT | (35.9M) | (12.7M) | (20.5M) | (123.1M) | (49.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026